Strength Seen in Gilead (GILD): Can Its 8.5% Jump Turn into More Strength?Zacks Investment Research • 06/21/24
Gilead surges as HIV prevention therapy shows 100% efficacy in late-stage trialProactive Investors • 06/20/24
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% EffectiveInvestors Business Daily • 06/20/24
Gilead's Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV PreventionBusiness Wire • 06/20/24
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss ContenderInvestors Business Daily • 06/17/24
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The RadarInvestors Business Daily • 06/14/24
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of TreatmentBusiness Wire • 06/14/24
Law Firms Speaking Out For The Thousands of California HIV Patients They Represent After Gilead's $40 Million Settlement Prompts Moral Reckoning for the HIV CommunityGlobeNewsWire • 06/13/24
Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 06/13/24
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNABusiness Wire • 06/06/24
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary CholangitisBusiness Wire • 06/05/24